Abstract:e13772 Background: Approximately 67% of cancer survivors were aged 65 or older in the U.S.; they face a heightened risk of frailty, as both cancer and anti-cancer treatment impose additional stressors on the older adults’ physiological reserves. Inflammatory biomarkers such as serum C-reactive protein (CRP) and Interleukin-6 (IL-6) levels were associated with frailty. However, the role of inflammatory biomarkers on the transitions of frailty states remains unclear. This study aimed to describe transitions between frailty states and death and quantify the predictive effect of inflammatory biomarkers on transitions. Methods: We used data from the National Health and Aging Trends Study (NHATS) from 2017 to 2022. A total of 1,219 older cancer survivors (>67 years) were included. Frailty was assessed annually using the Fried Frailty Phenotype (exhaustion, low physical activity, shrinking, low walking speed, and weakness) to categorize participants as “non-frail,” “pre-frail,” and “frail.” Inflammatory biomarkers were obtained via dried blood spots at baseline (2017). Plasma-equivalent values of CRP and IL-6 were used. Covariates included sex, age category, race, education level, marital status, obesity, and number of comorbidities. We defined four states that included three frailty states (non-frail, pre-frail, and frail) and an absorbing state of death. The multi-state Markov models were performed to capture possible transitions between frailty states and examine the effect of CRP and IL-6 on the five main transitions between states (non-frail to pre-frail, pre-frail to non-frail, pre-frail to frail, frail to pre-frail, frail to death). Results: At baseline, 25.27% were non-frail, 52.34% were pre-frail, and 22.40% were frail. During the follow-up time of 5 years, 1,396 transitions were observed, with 950 (68.05%) progressions (or to death) and 446 (31.95%) reversals. For participants who were non-frail, they were highly likely to develop pre-frailty (transition intensity=0.63). For participants with pre-frailty, progression to frailty was a little more likely than recovery to non-frailty (0.25 vs 0.21). Once entering the frail state, the likelihood of death outweighed that of recovery (0.30 vs 0.28). A higher level of CRP or IL-6 was associated with frailty progression (non-frail to pre-frail and frail to death), while a lower level of CRP or IL-6 was associated with recovery of frailty (pre-frail to non-frail and frail to pre-frail). Conclusions: This study is the first to investigate the longitudinal relationship between inflammatory biomarkers and frailty transitions in older cancer survivors using a nationally representative survey dataset. Our findings outlined potential transitions between frailty states and death, highlighting the role of elevated serum CRP and IL-6 levels on the increased risk of frailty progression and reduced risk of frailty recovery over 5 years.

Soluble TNFR1 has greater reproducibility than IL-6 for the assessment of chronic inflammation in older adults: the case for a new inflammatory marker in aging

Association of Immunity Markers with the Risk of Incident Frailty: the Rugao Longitudinal Aging Study

Level of IL-6, TNF, and IL-1β and age-related diseases: a systematic review and meta-analysis

Racial/Ethnic differences in inflammation levels among older adults 56+: an examination of sociodemographic differences across inflammation measure

Inflammatory biomarkers in older adults with frailty: a systematic review and meta-analysis of cross-sectional studies

Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength

C-reactive Protein, Frailty and Overnight Hospital Admission in Elderly Individuals: A Population-Based Study.

High Serum Tumor Necrosis Factor Receptor 1 Levels Are Related to Risk of Low Intrinsic Capacity in Elderly Adults

Association of two novel systemic inflammatory biomarkers and frailty based on NHANES 2007–2018

Longitudinal Analysis on Inflammatory Markers and Frailty Progression: Based on the English Longitudinal Study of Aging

THE ASSOCIATION BETWEEN INFLAMMATORY BIOMARKERS AND FRAILTY SYNDROME AMONG CHINESE OLD PEOPLE

Association of Midlife Inflammatory Markers With Cognitive Performance at 10-Year Follow-up

A link between systemic low-grade inflammation and frailty in older adults: clinical evidence from a nationwide population-based study

Combined Associations of Hs-Crp and Cognitive Function with All-Cause Mortality among Oldest-Old Adults in Chinese Longevity Areas: a Prospective Cohort Study

Study on the chronic low-grade inflammation and its related factors in the elderly

Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study

C-reactive Protein and White Blood Cell Are Associated with Frailty Progression: a Longitudinal Study

Inflammatory biomarkers and frailty transitions in older adults with cancer: Findings from a national cohort study.

sCD163, sCD28, sCD80, and sCTLA-4 as soluble marker candidates for detecting immunosenescence

Chronic Low-grade Inflammation in the Elderly

Impaired JAK-STAT pathway signaling in leukocytes of the frail elderly